English, Article edition: Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada Stephen Morris; Ed Godber

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119496
Physical Description
  • article
Language
  • English

Edition details

Title
  • Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada
Author
  • Stephen Morris
  • Ed Godber
Physical Description
  • article
Notes
  • Objective: To evaluate the effect of using different cost-effectiveness measures in the economic evaluation of cholesterol-modifying pharmacotherapy. Design and setting: An economic model was used to examine the extent to which the relative cost effectiveness of cholesterol-modifying agents varies depending upon the cost-effectiveness measure used. The perspective taken was that of the Canadian public healthcare system. Patients: Individuals without coronary heart disease (CHD) with low-density lipoprotein cholesterol (LDL-C) levels in excess of 190 mg/​dl. Interventions: Cholesterol-modifying pharmacotherapies available in Canada. Main outcome measures and results: Cost per 1% reduction in LDL-C level; incremental cost per life-year gained; least-cost agent achieving the LDL-C reduction required to meet the target level of 160 mg/​dl; incremental cost per life-year gained of agents reaching the target LDL-C level of 160 mg/​dl relative to no therapy; incremental cost per life-year gained of agents achieving the target LDL-C level of 160 mg/​dl relative to the least-cost agent reaching the target. Each cost-effectiveness measure had a different informational content to decision-makers, both in terms of the usefulness of the information they provided, and in terms of the extent to which they showed one agent to be more cost effective than another. The most cost-effective treatment regimens were fluvastatin 20mg per day, fluvastatin 40mg per day, atorvastatin 10mg per day and atorvastatin 20mg per day, depending on the pretreatment LDL-C level and the cost-effectiveness measure used. Conclusions: We recommend that the cost effectiveness of cholesterol-modifying pharmacotherapy be measured using incremental cost per life-year gained in reaching a predefined target LDL-C level.
  • Pharmacoeconomics, Coronary-disorders, Antihyperlipidaemics, Cost-effectiveness, Hyperlipidaemia
  • RePEc:wkh:phecon:v:16:y:1999:i:2:p:193-205
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment